Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL-Reference-Cited by-同舟云学术

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL

Published:2017-05-02 Issue:12 Volume:1 Page:715-727
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Kadri Sabah¹^ORCID,Lee Jimmy¹^ORCID,Fitzpatrick Carrie¹^ORCID,Galanina Natalie²^ORCID,Sukhanova Madina²^ORCID,Venkataraman Girish¹^ORCID,Sharma Shruti¹,Long Brad¹^ORCID,Petras Kristin¹,Theissen Megan¹,Ming Mei¹,Kobzev Yuri¹,Kang Wenjun³^ORCID,Guo Ailin¹,Wang Weige¹,Niu Nifang¹,Weiner Howard²,Thirman Michael²^ORCID,Stock Wendy²,Smith Sonali M.²^ORCID,Nabhan Chadi⁴^ORCID,Segal Jeremy P.¹,Lu Pin¹,Wang Y. Lynn¹^ORCID

Affiliation:

1. Department of Pathology,

2. Department of Medicine, and

3. Center for Research Informatics, University of Chicago, Chicago, IL; and

4. Cardinal Health Specialty Solutions, Waukegan, IL

Abstract

Key Points Del(18p), together with del(17p)/TP53 mutations, is present at a high frequency before ibrutinib treatment. BTK mutations drive ibrutinib relapse, but del(17p)/TP53 mutations may be dispensable.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/12/715/877185/advances003632.pdf

Reference43 articles.

1. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia;Byrd;N Engl J Med,2013

2. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies;Advani;J Clin Oncol,2013

3. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma;Wang;N Engl J Med,2013

4. A prospective multicenter study of the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom’s macroglobulinemia;Treon;Blood,2013

5. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study;Burger;Lancet Oncol,2014

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need;International Journal of Molecular Sciences;2024-01-27

2. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax;Clinical Cancer Research;2023-11-13

3. From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia;Cancer Treatment Reviews;2023-11

4. Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples;Blood;2023-08-03

5. Evaluation of the relative allelic load of mutations of resistance to ibrutinib in the <i>BTK</i> gene by allele-specific PCR in patients with progression of CLL;Russian journal of hematology and transfusiology;2023-07-18